General
At AbbVie, we are committed to providing treatment options for patients with ankylosing spondylitis (AS).
To learn more about a treatment option for your adult patients with active AS, please visit: https://abbv.ie/rv-aspdc.
©2022 Abbvie Ltd. All rights reserved.
US-IMMR-220141 August 2022
General
AS Diagnosis: Lessons from Two Rheumatologists’ Journeys
With approximately 3 out of every 1000 people in North America living with ankylosing spondylitis (AS), based on a 2013 prevalence study, properly targeted care and diagnoses are key. Watch these videos to learn about two rheumatologists’ journeys as AS patients, and explore how you can help patients manage this disease and help get them back to their daily activities.
The AS Journey – Chapter 1: https://bcove.video/36ZB6No
The AS Journey – Chapter 2: https://bcove.video/3DDzbKk
Reference: 1. Dean, LE Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53(4):650-657. doi:10.1093/rheumatology/ket387
©2022 Abbvie Ltd. All rights reserved.
General
The new Pfizer Medical portal is now live
The new Pfizer Medical portal is a personalized digital experience that easily connects you to cross-therapeutic Pfizer medical content and experts—all in one place.
Explore these resources at pfizermedical.pfizerpro.com.
Pfizer Medical is your centralized source of clinical knowledge of Pfizer’s medicines and vaccines.
For more tailored content, create an account and select your therapeutic area.
General
A manuscript has been published on ORAL Surveillance within the January 27 issue of the New England Journal of Medicine. The manuscript is entitled Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. This peer-reviewed publication reports results from the Oral Rheumatoid Arthritis Trial (ORAL) Surveillance, a randomized, post-marketing requirement study with the primary objective of evaluating the safety of tofacitinib at two doses (5mg twice daily and 10 mg twice daily) compared with a TNF inhibitor in patients with rheumatoid arthritis who were 50 years of age or older and had at least one cardiovascular risk factor. The publication is available here.
The XELJANZ® (tofacitinib) US Prescribing Information can be found here.
General
On December 14, 2021, Pfizer received FDA approval of XELJANZ® 5 mg twice daily (BID) and XELJANZ® XR (tofacitinib) extended release 11 mg once daily (QD) for the treatment of adult patients with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more TNF blockers.
The approval was based on data from the Phase 3 AS clinical development program, which consisted of a 48-week study that evaluated the safety and efficacy of XELJANZ in adult patients with active AS. Pfizer’s press release and XELJANZ® (tofacitinib) approved product labeling can be found here and here.